These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34373315)

  • 1. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol.
    de Celis-Ruiz E; Fuentes B; Moniche F; Montaner J; Borobia AM; Gutiérrez-Fernández M; Díez-Tejedor E
    BMJ Open; 2021 Aug; 11(8):e051790. PubMed ID: 34373315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial.
    de Celis-Ruiz E; Fuentes B; Alonso de Leciñana M; Gutiérrez-Fernández M; Borobia AM; Gutiérrez-Zúñiga R; Ruiz-Ares G; Otero-Ortega L; Laso-García F; Gómez-de Frutos MC; Díez-Tejedor E
    Cell Transplant; 2022; 31():9636897221083863. PubMed ID: 35301883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial.
    Díez-Tejedor E; Gutiérrez-Fernández M; Martínez-Sánchez P; Rodríguez-Frutos B; Ruiz-Ares G; Lara ML; Gimeno BF
    J Stroke Cerebrovasc Dis; 2014; 23(10):2694-2700. PubMed ID: 25304723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with Acute Ischaemic stRoke (J-REPAIR).
    Suda S; Nito C; Ihara M; Iguchi Y; Urabe T; Matsumaru Y; Sakai N; Kimura K;
    BMJ Open; 2022 May; 12(5):e054269. PubMed ID: 35613802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of butylphthalide for patients who had acute ischaemic stroke receiving intravenous thrombolysis or endovascular treatment (BAST trial): study protocol for a randomised placebo-controlled trial.
    Zhang X; Wang A; Zhang JY; Jia B; Huo X; Zuo Y; Tian X; Wang Y; Miao Z;
    BMJ Open; 2021 May; 11(5):e045559. PubMed ID: 34035100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial).
    Soria-Juan B; Garcia-Arranz M; Llanos Jiménez L; Aparicio C; Gonzalez A; Mahillo Fernandez I; Riera Del Moral L; Grochowicz L; Andreu EJ; Marin P; Castellanos G; Moraleda JM; García-Hernández AM; Lozano FS; Sanchez-Guijo F; Villarón EM; Parra ML; Yañez RM; de la Cuesta Diaz A; Tejedo JR; Bedoya FJ; Martin F; Miralles M; Del Rio Sola L; Fernández-Santos ME; Ligero JM; Morant F; Hernández-Blasco L; Andreu E; Hmadcha A; Garcia-Olmo D; Soria B
    Trials; 2021 Sep; 22(1):595. PubMed ID: 34488845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of human-derived neural stem cell in patients with ischaemic stroke: study protocol for a randomised controlled trial.
    Xie C; Wang K; Peng J; Jiang X; Pan S; Wang L; Wu Y; Guan Y
    BMJ Open; 2022 Nov; 12(11):e055108. PubMed ID: 36351721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Hess DC; Wechsler LR; Clark WM; Savitz SI; Ford GA; Chiu D; Yavagal DR; Uchino K; Liebeskind DS; Auchus AP; Sen S; Sila CA; Vest JD; Mays RW
    Lancet Neurol; 2017 May; 16(5):360-368. PubMed ID: 28320635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.
    Houkin K; Osanai T; Uchiyama S; Minematsu K; Taguchi A; Maruichi K; Niiya Y; Asaoka K; Kuga Y; Takizawa K; Haraguchi K; Yoshimura S; Kimura K; Tokunaga K; Aoyama A; Ikawa F; Inenaga C; Abe T; Tominaga A; Takahashi S; Kudo K; Fujimura M; Sugiyama T; Ito M; Kawabori M; Hess DC; Savitz SI; Hirano T;
    JAMA Neurol; 2024 Feb; 81(2):154-162. PubMed ID: 38227308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
    Hill MD; Goyal M; Menon BK; Nogueira RG; McTaggart RA; Demchuk AM; Poppe AY; Buck BH; Field TS; Dowlatshahi D; van Adel BA; Swartz RH; Shah RA; Sauvageau E; Zerna C; Ospel JM; Joshi M; Almekhlafi MA; Ryckborst KJ; Lowerison MW; Heard K; Garman D; Haussen D; Cutting SM; Coutts SB; Roy D; Rempel JL; Rohr AC; Iancu D; Sahlas DJ; Yu AYX; Devlin TG; Hanel RA; Puetz V; Silver FL; Campbell BCV; Chapot R; Teitelbaum J; Mandzia JL; Kleinig TJ; Turkel-Parrella D; Heck D; Kelly ME; Bharatha A; Bang OY; Jadhav A; Gupta R; Frei DF; Tarpley JW; McDougall CG; Holmin S; Rha JH; Puri AS; Camden MC; Thomalla G; Choe H; Phillips SJ; Schindler JL; Thornton J; Nagel S; Heo JH; Sohn SI; Psychogios MN; Budzik RF; Starkman S; Martin CO; Burns PA; Murphy S; Lopez GA; English J; Tymianski M;
    Lancet; 2020 Mar; 395(10227):878-887. PubMed ID: 32087818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial.
    Fu Y; Tang R; Chen R; Wang A; Ren J; Zhu S; Feng X; Fan D
    Stroke Vasc Neurol; 2024 Feb; 9(1):90-95. PubMed ID: 37308251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.
    van Rhijn-Brouwer FCC; Gremmels H; Fledderus JO; Schuurman AH; Bonte-Mineur F; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Coert JH; Radstake TRDJ; van Laar JM; Verhaar MC;
    BMJ Open; 2018 Aug; 8(8):e020479. PubMed ID: 30127049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.